The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. Jalleh RJ, Talley NJ, Horowitz M, Nauck MA, et al. J Clin Invest 2026;136:e194740.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jalleh RJ, Talley NJ, Horowitz M, Nauck MA, et al. The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. J Clin Invest 2026;136:e194740.
PMID: 41697736